Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique
- PMID: 26498943
- PMCID: PMC4635174
- DOI: 10.1007/s12325-015-0249-6
Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique
Abstract
Introduction: There is a lack of agreed and established guidelines for the treatment of acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF). This reflects, in part, the limited evidence-base underpinning the management of AE-IPF. In the absence of high-quality evidence, the aim of this research was to develop a clinician-led consensus statement for the definition, diagnosis and treatment of AE-IPF.
Methods: A literature review was conducted to obtain published material on the definition and treatment of AE-IPF. The results of this review were circulated to an online panel of clinicians for review. Statements were then shared with ten expert respiratory clinicians who regularly treat patients with IPF. A Delphi technique was then used to develop a consensus statement for the definition, diagnosis and treatment of AE-IPF. During the first round of review, clinicians rated the clarity of each statement, the extent to which the statement should be included and provided comments. In two subsequent rounds of review, clinicians were provided with the group median inclusion rating for each statement, and any revised wording of statements to aid clarity. Clinicians were asked to repeat the clarity and inclusion ratings for the revised statements.
Results: The literature review, online panel discussion, and face-to-face meeting generated 65 statements covering the definition, diagnosis, and management of AE-IPF. Following three rounds of blind review, 90% of clinicians agreed 39 final statements. These final statements included a definition of AE-IPF, approach to diagnosis, and treatment options, specifically: supportive measures, use of anti-microbials, immunosuppressants, anti-coagulants, anti-fibrotic therapy, escalation, transplant management, and long-term management including discharge planning.
Conclusion: This clinician-led consensus statement establishes the 'best practice' for the management and treatment of AE-IPF based on current knowledge, evidence, and available treatments.
Keywords: Acute exacerbations; Acute lung injury; Best practice; Consensus statement; Definition; Diagnosis; Idiopathic pulmonary fibrosis; Interstitial lung disease; Qualitative research; Treatment.
Figures
Similar articles
-
Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF): an overview of current and future therapeutic strategies.Expert Rev Respir Med. 2020 Apr;14(4):405-414. doi: 10.1080/17476348.2020.1724096. Epub 2020 Feb 3. Expert Rev Respir Med. 2020. PMID: 31994940 Review.
-
Translating Idiopathic pulmonary fibrosis guidelines into clinical practice.Pulmonology. 2021 Jan-Feb;27(1):7-13. doi: 10.1016/j.pulmoe.2020.05.017. Epub 2020 Jun 16. Pulmonology. 2021. PMID: 32561352
-
Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study.BMC Pulm Med. 2020 Jul 14;20(1):191. doi: 10.1186/s12890-020-01209-4. BMC Pulm Med. 2020. PMID: 32664913 Free PMC article.
-
Acute exacerbations of fibrotic interstitial lung diseases.Respirology. 2020 May;25(5):525-534. doi: 10.1111/resp.13682. Epub 2019 Aug 19. Respirology. 2020. PMID: 31426125
-
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review.Intern Emerg Med. 2015 Jun;10(4):401-11. doi: 10.1007/s11739-015-1204-x. Epub 2015 Feb 12. Intern Emerg Med. 2015. PMID: 25672832 Free PMC article. Review.
Cited by
-
An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis.ERJ Open Res. 2024 Jan 29;10(1):00636-2023. doi: 10.1183/23120541.00636-2023. eCollection 2024 Jan. ERJ Open Res. 2024. PMID: 38288082 Free PMC article.
-
Development of a core dataset for child injury surveillance: a modified Delphi study in China.Front Pediatr. 2023 Apr 28;11:970867. doi: 10.3389/fped.2023.970867. eCollection 2023. Front Pediatr. 2023. PMID: 37187581 Free PMC article.
-
The contribution of infection and the respiratory microbiome in acute exacerbations of idiopathic pulmonary fibrosis.Eur Respir Rev. 2019 Jul 8;28(152):190045. doi: 10.1183/16000617.0045-2019. Print 2019 Jun 30. Eur Respir Rev. 2019. PMID: 31285290 Free PMC article. Review.
-
Impact of lymphocyte differential count > 15% in BALF on the mortality of patients with acute exacerbation of chronic fibrosing idiopathic interstitial pneumonia.BMC Pulm Med. 2017 Apr 20;17(1):67. doi: 10.1186/s12890-017-0412-8. BMC Pulm Med. 2017. PMID: 28427425 Free PMC article.
-
The Role of Infection in Interstitial Lung Diseases: A Review.Chest. 2017 Oct;152(4):842-852. doi: 10.1016/j.chest.2017.03.033. Epub 2017 Apr 8. Chest. 2017. PMID: 28400116 Free PMC article. Review.
References
-
- American Thoracic Society Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS) Am J Respir Crit Care Med. 2000;161((2 Pt 1)):646–664. - PubMed
-
- American Thoracic S. European Respiratory S American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277–304. doi: 10.1164/ajrccm.165.2.ats01. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources